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Introduction
Almost one in ﬁve adults within the European Union
suffers from chronic pain (1), imposing a signiﬁcant
burden on their quality of life (QoL). Persistent
chronic pain is associated with depression and anxi-
ety, interference with work and personal relationships
and loss of independence (2).
As recommended by the World Health Organiza-
tion, opioids have become the established treatment
for moderate-to-severe chronic cancer pain (3) and,
in recent years, have also become a mainstay for the
treatment of chronic non-cancer pain. Oxycodone is
a semi-synthetic, opioid analgesic that has demon-
strated effectiveness in treating cancer and non-cancer
related pain (4–9). However, the primary disadvan-
tage associated with these agents is the development
of opioid-induced bowel dysfunction (OIBD) in
many patients, which commonly manifests as signiﬁ-
cant constipation (10).
Opioid-induced bowel dysfunction is a conse-
quence of the action of opioids on receptors within
the gastrointestinal (GI) tract, which reduce GI
motility, inhibit secretion, increase absorption, affect
blood ﬂow and increase anal sphincter tone (10). As
a result, patients can experience a range of symptoms
such as straining, incomplete evacuation, bloating,
abdominal distension and increased gastric reﬂux
(10). Constipation is the most frequently-reported
adverse event in patients receiving opioid treatment
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remained low and stable during this study. Adverse events in both extension
phases were consistent with those associated with opioid therapy; no additional
safety concerns were observed. Conclusion: Results from these two open-label
extension studies demonstrate the long-term efﬁcacy and tolerability of ﬁxed com-
bination oxycodone PR⁄naloxone PR in the treatment of chronic pain. Patients
experienced clinically relevant improvements in OIBD while receiving effective anal-
gesic therapy.
What’s known
The ﬁxed combination of oxycodone PR/ naloxone
PR was shown to be tolerable and effective in
providing analgesia and improving bowel function
in a 12 weeek randomised, controlled study setting.
What’s new
The ﬁxed combination of oxycodone PR and
naloxone PR is a safe and efﬁcacious agent also for
the long-term treatment of chronic pain.
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doi: 10.1111/j.1742-1241.2010.02360.x 763(11). Unlike most adverse events associated with opi-
oid use, which subside with chronic use, opioid-
induced constipation (OIC) persists in many patients
(12). The pain and discomfort caused by OIC can
cause patients to reduce or even discontinue their
opioid therapy (13), resulting in inadequate analgesia
and further impairment of QoL (14,15).
Current management strategies for OIC are non-
speciﬁc and often ineffective (16). Laxatives can
improve symptoms in some patients; however, as
this strategy fails to address the underlying opioid
receptor-mediated mechanism of bowel dysfunction
that leads to constipation in these patients, a sub-
stantial number do not achieve adequate relief of
symptoms (10,13). In addition, laxatives can be
associated with several drawbacks (10,17), and fur-
thermore, long-term laxative use can be associated
with damage to the muscular function of the bowel;
nutritional deﬁcits in terms of loss of water, vita-
mins and minerals; and kidney stones or renal fail-
ure, in addition to modifying the effects of other
medicines.
Prevention of OIC, and bowel dysfunction in gen-
eral, is considered to be a more effective therapeutic
strategy than merely treating the symptoms as they
occur (13). One approach to targeting the underlying
cause of OIC is the oral co-administration of opioids
and opioid antagonists with limited systemic bio-
availability. By acting locally within the gut to block
opioid action, the opioid antagonist would prevent
or minimise OIBD, while the lack of systemic activity
would mean no reduction in the central analgesic
effects of the opioid.
Naloxone is an opioid-receptor antagonist that,
when administered orally, has a very low systemic
bioavailability of < 3% (16) because of extensive
ﬁrst-pass hepatic metabolism (18). As a result, nalox-
one acts almost exclusively on opioid receptors in
the GI tract (19). Results from a pharmacokinetic
study in healthy subjects demonstrated that co-
administration of oxycodone prolonged release
(PR)⁄naloxone PR in a ﬁxed dose combination does
not signiﬁcantly affect the bioavailability of either of
its constituents (20). As such, the oral co-administra-
tion of oxycodone PR⁄naloxone PR has been shown
to provide an effective analgesia for patients with
severe chronic pain, and to signiﬁcantly reduce the
impact of OIC (21).
The efﬁcacy and tolerability of the ﬁxed combina-
tion of oxycodone PR⁄naloxone PR has been shown
in two Phase III, double-blind, randomised con-
trolled clinical trials, one focusing on analgesic efﬁ-
cacy and the other focusing on bowel function. The
ﬁrst showed oxycodone PR⁄naloxone PR to be supe-
rior to placebo in terms of analgesic efﬁcacy while
also providing signiﬁcant beneﬁts in terms of bowel
function (22). Furthermore, the addition of naloxone
PR to oxycodone PR in a ﬁxed combination formu-
lation did not negatively impact on the analgesic efﬁ-
cacy of oxycodone PR. In the second Phase III trial,
patients receiving the ﬁxed combination of oxyco-
done PR⁄naloxone PR experienced signiﬁcant
improvements in OIC compared with those receiving
oxycodone PR, with comparable analgesia (23). In
addition, clinically relevant improvements in bowel
function have been observed in patients with chronic
pain treated with oxycodone PR⁄naloxone PR, com-
pared with oxycodone PR alone (24). Naloxone
PR⁄oxycodone PR has also been shown to improve
patient assessment of analgesic opioid therapy for
severe chronic pain, in terms of both efﬁcacy and
tolerability (25).
This report presents the results of the open-label
extensions of the aforementioned two Phase III stud-
ies (22,23), one examining the long-term analgesic
efﬁcacy of oxycodone PR⁄naloxone and the other
investigating bowel function. The tolerability of the
ﬁxed combination of oxycodone PR⁄naloxone PR in
the treatment of patients with moderate-to-severe
non-cancer pain was also assessed in both open-label
extension phases.
Methods
These were uncontrolled, open-label, extension phase
studies in patients with non-cancer pain, who had
completed one of two previous randomised, con-
trolled, 12-week studies (22,23), performed to assess
the efﬁcacy and safety of oxycodone PR⁄naloxone
PR for an additional 52 weeks. Both studies were
conducted in accordance with the Declaration of
Helsinki (26) and all of its accepted amendments
to date and all relevant German laws, as well as
complying with the International Conference for
Harmonisation Guideline for Good Clinical Practice
(27) and the European Union Clinical Trials
Directive 2001⁄20⁄EC (28). Written consent was
obtained from all participants prior to study
commencement.
Patient population
All patients who completed one of the previous dou-
ble-blind studies (22,23), who required daily opioid
therapy and who were likely to beneﬁt from treat-
ment for the duration of the study were eligible to
enter the respective extension phase. These patients
were males and females who were at least 18 years
old with a history of moderate-to-severe, non-malig-
nant pain that had been effectively managed with
daily opioid therapy for at least 2 weeks before entry
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Patients with a history of hypersensitivity to oxyco-
done, naloxone or any related product, a diagnosis
of cancer (not including basal cell carcinoma), clini-
cally signiﬁcant cardiovascular, renal, hepatic, GI or
psychiatric disease that would have placed the patient
at risk upon exposure to the study medication or
that could confound the analysis and⁄or interpreta-
tion of the study results were excluded from the
study. Other exclusion criteria included active alco-
hol or substance abuse, and abnormal liver function
tests. In the analgesia study, patients with a history
of more than two lower back surgeries and those
receiving the equivalent of < 10 mg or > 40 mg oxy-
codone per day were also excluded.
At the start of the double-blind phase of the
bowel function study, patients had to be experienc-
ing constipation caused or aggravated by opioids,
be willing to discontinue their current laxative regi-
men and comply with the use of oral bisacodyl as a
laxative rescue medication. Laxative rescue medica-
tion was permitted no sooner than 72 h after the
patient’s most recent bowel movement; however, if
patients experienced discomfort during this period,
they could take bisacodyl 5 mg as a laxative earlier
than 72 h after their most recent bowel movement,
as required, to treat constipation. The maximum
total amount of oral bisacodyl permitted was ﬁve
doses within seven consecutive days. Patients taking
daily ﬁbre supplementation or bulking agents were
eligible for inclusion if they could be maintained on
a stable dose and regimen throughout the study
and were considered able to maintain adequate
hydration.
Study design
In the extension phase of both studies, patients’
pain was treated with open-label study medication
(oxycodone PR⁄naloxone PR) for up to 12 months
(Figure 1). In the analgesia extension study, all
patients were initially switched to 20⁄10 mg oxyco-
done PR⁄naloxone PR per day to prevent patients
who had received placebo in the double-blind
study from being given an initial high dose of opi-
oid. In the bowel function study, the initial starting
dose of oxycodone PR⁄naloxone PR was the effec-
tive analgesic dose, based on the oxycodone dose
that the patient was receiving at the end of the
double-blind phase. Dose titration up to 80⁄40 mg
oxycodone PR⁄naloxone PR per day was permitted
A
B
Figure 1 Study design of (A) the analgesia study and (B) the bowel function study. OXN, oxycodone PR⁄naloxone PR;
OXY, oxycodone PR; OXYIR, oxycodone immediate-release; R, randomisation
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In both studies, immediate-release (IR) oxycodone
was provided as study medication during the ﬁrst
7 days of the extension phase for titration. After
this period investigators could prescribe also other
analgesic rescue medicine, if needed. In the bowel
function study, bisacodyl was also provided as res-
cue medication only during the ﬁrst 7 days of the
extension phase. Any additional laxative treatment
was by consultation with the investigator.
Efﬁcacy outcomes and assessments
The extension studies were conducted primarily to
assess the long-term safety of the ﬁxed combination
of oxycodone PR⁄naloxone PR in the treatment of
chronic non-cancer pain. No deﬁned primary end-
point was set; however, analgesic efﬁcacy and bowel
function were assessed.
Analgesia study
The objective of the analgesia study was to assess
pain and interference of pain with activities during
treatment with oxycodone PR⁄naloxone PR, based
on the modiﬁed Brief Pain Inventory–Short Form
(BPI-SF) (29). The modiﬁed BPI-SF consists of 12
questions designed to assess the severity of patients’
pain and the impact of pain on daily functions. The
pain subscale consists of the ﬁrst four questions
[numerical rating scale (NRS) 0–10: 0 = no pain;
10 = pain as bad as you can imagine]. The interfer-
ence subscale consists of questions 6–12 (NRS 0–10:
0 = does not interfere; 10 = completely interferes)
and question 5 reﬂects pain relief (NRS 0–10: 0 = no
relief; 10 = complete relief). The study also assessed
changes in the dose of oxycodone PR⁄naloxone PR
during the study period. Study medication intake
(time and dose) was recorded by the investigators;
change in dose from the randomised dose to the
end of the extension phase, as well as after 2 weeks
of the extension phase, was assessed as an efﬁcacy
parameter.
Bowel function study
The objective of this study was to assess whether
patients with moderate-to-severe non-cancer pain
taking oxycodone PR⁄naloxone PR had improve-
ments in bowel function, as measured by the vali-
dated Bowel Function Index (BFI) (30, 32) at each
study visit over 52 weeks. The BFI score of each
patient was deﬁned as the mean score of three dis-
tinct components: ease of defaecation [numerical
analogue scale (NAS) 0–100: 0 = easy⁄no difﬁculty;
100 = severe difﬁculty]; feeling of incomplete bowel
evacuation (NAS 0–100: 0 = not at all, 100 = very
strong); and judgement of constipation (NAS 0–100:
0 = not at all; 100 = very strong). Each question
referred to the patient’s experience during the past
7 days, with higher scores indicating poor bowel
function. Average pain over the last 24 h was also
assessed at each study visit using the Pain Intensity
Scale (NRS 0–10), and frequency of rescue medica-
tion and laxative use was measured.
Safety assessments
Safety assessments consisted of monitoring all
adverse events (AEs), including serious adverse
events (SAEs); monitoring haematology, blood chem-
istry and urine values; periodic measurement of vital
signs and electrocardiograms (ECGs); and physical
examinations. In the bowel function study, symp-
toms of opioid withdrawal were also assessed using
the Subjective Opiate Withdrawal Scale (SOWS)
(31).
Statistical analysis
The extension study population consisted of all
patients who received at least one dose of oxycodone
PR⁄naloxone PR in the extension phase. In the anal-
gesia study, a subpopulation was deﬁned post hoc,
consisting of patients who received oxycodone
PR⁄naloxone PR > 40 mg⁄20 mg per day on
> 7 days consecutively. In the bowel function study,
a post hoc analysis was conducted to examine changes
in BFI score according to treatment received in the
double-blind phase.
Analgesia study efﬁcacy analysis
Summary statistics were provided for each single
item and each subscale of the BPI-SF using the
last observation carried forward (LOCF) method
for missing values. Summary statistics of average
pain over 24 h, the pain subscale, the sleep inter-
ference and the interference subscale were also dis-
played for observed values without any missing
values. Changes in dose were assessed using a shift
table with numbers of changes from the dose at
the start of the double-blind phase to the oxyco-
done PR⁄naloxone PR dose at the end of the
extension phase, as well as the oxycodone PR⁄
naloxone PR dose after 2 weeks of the extension
phase. Changes in dose after 2 weeks of the exten-
sion phase were grouped according to double-blind
phase treatment.
Bowel function study efﬁcacy analysis
Continuous efﬁcacy variables were summarised by n
(i.e. the number of non-missing values), mean (i.e.
arithmetic average) and standard deviation (SD),
whereas number and percentage were used to sum-
marise categorical efﬁcacy variables.
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For the safety data analyses, all continuous variables
were summarised by n (i.e. the number of non-missing
values), mean (i.e. arithmetic average) and SD. The
number and percentage of observed levels were
reported for all categorical measures. AEs were classi-
ﬁed by system organ class and Medical Dictionary for
Regulatory Activities (MedDRA)-preferred term. The
incidence of AEs considered as having a causal rela-
tionship to study medication (unlikely, possible, prob-
able or deﬁnite) was also recorded. In the analgesia
study, the incidence of GI AEs and nervous system
disorders was recorded for 0–3 months, 3–6 months,
6–9 months, 9–12 months, > 12 months and follow up.
Results
Analgesia study
Of the 464 patients who were initially randomised,
463 received study medication and entered the dou-
ble-blind phase. Of these patients, 380 (81.9%) con-
tinued to the extension phase and 379 received study
medication. The majority of patients (78%) com-
pleted the 12-month study, with 86% remaining in
the study at 6 months. Only 83 patients (22%) had
discontinued the study by 12 months; the majority
of these discontinuations were resulting from the
patients’ choice (31 patients, 8.2%), administrative
error (15 patients, 4.0%) or patients being lost to
follow up (one patient, 0.3%) (Figure 2A). AEs were
responsible for 24 (6.3%) patient discontinuations,
and 12 (3.2%) discontinuations were resulting from
lack of therapeutic effect.
Patients were 56.2 years in average, with 39% male
and 61% female; all were Caucasian (Table 1). The
average equivalent dose of oxycodone taken in the
full analysis population during the extension phase
was 40.9 mg⁄day, and the mean exposure to study
medication was 320.5 days (median = 365 days). In
the subpopulation of patients who received oxycodone
A
B
Figure 2 Patient disposition in (A) the analgesia study and (B) the bowel function study
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days consecutively, the average dose of oxycodone
was 67.8 mg⁄day, and the mean number of days
patients were on doses > 40 mg⁄20 mg oxycodone
PR⁄naloxone PR was 244.5 days.
Efﬁcacy evaluation
The objective of the extension study was to assess
the long-term analgesic efﬁcacy of oxycodone
PR⁄naloxone PR for up to 12 months. After entering
the extension phase, the mean pain score (± SD) for
the BPI-SF item ‘average pain over the last 24 h’ was
3.9 ± 1.52 (Week 1), which was comparable with the
mean score at the end of the double-blind phase
(Table 2). Mean pain scores (±SD) remained low
and stable over 6 months (3.7 ± 1.59) and
12 months (3.8 ± 1.72), indicating effective long-
term analgesia with oxycodone PR⁄naloxone PR
(Figure 3). At Week 1, the mean score on the BPI-SF
pain subscale (±SD) was 15.3 ± 6.18, and this
remained low and stable over 6 months
(14.6 ± 6.67) and 12 months (14.8 ± 6.93), conﬁrm-
ing effective long-term analgesia with oxycodone
PR⁄naloxone PR (Table 2).
The mean score (±SD) for the BPI-SF item ‘sleep
interference’ was 2.9 ± 2.52 after switching to the
extension phase (Week 1), which was comparable with
the mean score at the end of the double-blind phase
(Table 2). Mean sleep interference scores (±SD)
remained low and stable over 6 months (3.2 ± 2.50)
and 12 months (3.1 ± 2.48), which correlated well
with the low BPI-SF pain scores, indicating a beneﬁcial
effect of oxycodone PR⁄naloxone PR on sleep quality.
After entering the extension phase (Week 1), the mean
BPI-SF interference subscore (±SD) was 21.2 ± 12.54,
which remained low and stable over 6 months
(22.4 ± 12.77) and 12 months (23.0 ± 13.00); this
correlated well with the low BPI-SF pain scores and
indicated a positive effect on pain with activities.
In the subgroup of patients using daily oxycodone
PR⁄naloxone PR doses greater than 40⁄20 mg, the
mean average pain score (±SD) at the end of the
double-blind phase was 4.2 ± 1.4; this remained sta-
ble throughout the study (varying between 4.1 and
4.3), being 4.2 ± 1.74 at 12 months. These pain
scores were comparable with those of the total exten-
sion population, and no clinically relevant differences
could be observed throughout the 12-month exten-
sion phase.
After the ﬁrst 2 weeks of the extension phase, the
majority of patients remained on a dose of oxyco-
done PR⁄naloxone PR that was comparable with the
dose they had received in the double-blind phase. A
total of 53.8% of patients remained on the same dose
as they received in the double-blind phase. The per-
centage of patients who had a decrease or increase in
dose was comparable between, and independent of,
the different double-blind phase treatment groups
from which the patients had been switched (Table 3).
Table 1 Patient baseline demographics
Analgesia
study (n = 379)
Bowel function
study (n = 258)
Sex, n (%)
Male 148 (39) 102 (39.5)
Female 231 (61) 156 (60.5)
Age, years
Mean ± SD 56.2 ± 10.88 58.4 ± 11.91
Weight, kg
Mean ± SD 83.2 ± 17.87 85.4 ± 18.56
SD, standard deviation.
Table 2 Mean change in BPI-SF items by study visit [analgesia study; LOCF; extension population (N = 379)]
BPI-SF item
Visit
Average pain
over the last
24 h (0–10)
Mean ± SD
Sleep quality
item (0–10)
Mean ± SD
Pain
subscale
(0–40)
Mean ± SD
Interference
subscale (0–70)
Mean ± SD
End of double-blind study 3.8 ± 1.48 3.1 ± 2.67 15.3 ± 6.09 21.6 ± 13.10
Week 1 3.9 ± 1.52 2.9 ± 2.52 15.3 ± 6.18 21.2 ± 12.54
3 months 3.8 ± 1.60 3.0 ± 2.48 14.7 ± 6.55 22.2 ± 12.80
6 months 3.7 ± 1.59 3.2 ± 2.50 14.6 ± 6.67 22.4 ± 12.77
9 months 3.7 ± 1.66 3.3 ± 2.64 14.8 ± 6.70 23.0 ± 13.23
12 months 3.8 ± 1.72 3.1 ± 2.48 14.8 ± 6.93 23.0 ± 13.00
BPI-SF, Brief Pain Inventory – Short Form; LOCF, last observation carried forward; SD, standard deviation.
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increased slightly from 35.6 ± 16.53 mg after 2 weeks
to 43.7 ± 22.53 mg at the end of the extension
phase, indicating a natural progression of the under-
lying chronic pain condition over this period.
Safety evaluation
Overall, the incidence of AEs in the extension phase
(68%) was comparable with that in the double-blind
phase (oxycodone PR⁄naloxone PR 55.8%; oxyco-
done PR 53.0%; placebo 52.5%), taking into account
the longer observation period. Most AEs were mild
or moderate, and the incidence of severe AEs was
low (13%). For the majority of AEs (62%), no action
was taken regarding the study drug. In the subgroup
of patients using oxycodone PR⁄naloxone PR doses
greater than 40⁄20 mg daily, the incidence of AEs
was slightly higher than in the overall population,
during the extension phase (71.6 vs. 68.0% respec-
tively).
The incidence of AEs considered as having a causal
relationship to study medication was 38% and the
number of AEs leading to treatment discontinuation
was 6.3%. Constipation (9.2%), nausea (7.7%), back
pain (6.3%) and depression (6.3%) were the most
frequently reported AEs (Table 4). The incidence of
GI AEs in the extension phase (28%) was compara-
ble with that in the double-blind phase (24.4%) and
was the highest in the ﬁrst 3 months of the extension
phase. Constipation was assessed by the investigator
as not being related to study medication in 2.9% of
patients; therefore, the incidence of treatment-related
Figure 3 Brief Pain Inventory-Short Form item ‘average pain over the last 24 h’ – mean score by visit: analgesia study
(n = 379). BPI-SF, Brief Pain Inventory – Short Form
Table 3 Number of patients with a dose increase or
decrease after the ﬁrst 2 weeks of the extension phase
grouped by double-blind medication: analgesia study
Treatment during
double-blind phase
Decrease in
dose, n (%)
Increase in
dose, n (%)
Oxycodone PR⁄naloxone PR
20 mg⁄10 mg 0 (0) 22 (37)
40 mg⁄20 mg 17 (24) 19 (27)
Oxycodone PR
20 mg 3 (5) 24 (37)
40 mg 8 (15) 18 (33)
Placebo
20 mg 2 (3) 33 (46)
40 mg 9 (17) 20 (38)
PR, prolonged release.
Table 4 Incidence of adverse events reported by system
organ class (‡ 10%) and preferred term (‡ 6%):
analgesia study extension population
Oxycodone
PR⁄naloxone PR
n = 379 %
Any adverse event 258 68
GI disorders 106 28
Constipation 35 9.2
Nausea 29 7.7
Infections and infestations 82 22
Nasopharyngitis 20 5.3
Musculoskeletal and connective
tissue disorders
79 21
Back pain 24 6.3
Nervous system disorders 53 14
Psychiatric disorders 41 11
Depression 24 6.3
Skin and subcutaneous tissue
disorders
41 11
General disorders 39 10
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concomitant laxative medication during the exten-
sion phase and 8.7% had regular laxative intake.
Diarrhoea was experienced by 3.2% of patients,
although only 1.3% was considered to be related to
oxycodone PR⁄naloxone PR.
The overall incidence of nervous system disorders
was 14% (Table 4), being the highest in the ﬁrst
3 months of the extension phase. Two patients
reported an AE related to opioid withdrawal (drug
withdrawal syndrome); however, both AEs started
after the end of study medication intake and were,
therefore, probably related to the change of opioid
treatment. There were no treatment-related deaths
during the course of the study.
Overall, 48 patients (13%) experienced 88 SAEs.
Of these, 27 events in 12 patients were considered to
have a causal relationship to study medication, but
only six events in three patients were considered by
the investigators to have a possible relationship to
the study medication, and included confusional state,
urge incontinence and depression in one patient,
cholecystitis acute and cholelithiasis in one patient,
and dyspepsia in one patient. No remedial action
was deemed necessary in these three patients who
recovered from these AEs. The sponsor also assessed
the causality of the SAEs. In this regard, four SAEs
were considered to have a stronger relationship to
the study drug compared with the assessment of the
investigator. A hypertensive crisis and epilepsy attack
in two patients were assessed as possibly related,
whereas arterial hypertension and abdominal pain in
two other patients were assessed as unlikely related
to the study drug. As a result, 30 events in 14
patients were considered by the sponsor to have a
possible relationship with study medication. Overall,
treatment was discontinued for four patients with
SAEs that were considered causally related to the
study drug.
After 6 and 12 months, the majority of the clinical
laboratory values were normal. No clinically relevant
changes in vital signs were observed during the study
and ECG abnormalities were isolated.
Bowel function study
A total of 258 patients (80.1%) of the 322 who were
randomised in the double-blind phase entered the
extension study and received the ﬁxed combination
oxycodone PR⁄naloxone PR. The majority of these
patients (227, 88%) completed the study. Of the 31
patients (12%) who discontinued the study, 9 (3.5%)
did so through choice, 4 (1.6%) did so because of
administrative error and 3 (1.2%) were lost to follow
up (Figure 2B). The cause of discontinuation was
AEs in 12 patients (4.7%) and lack of therapeutic
effect in three patients (1.2%).
Patients were 58.4 years in average, with 102
(39.5%) male and 156 (60.5%) female patients
(Table 1). The average dose of oxycodone PR⁄nalox-
one PR received by the extension-phase population
was 38.3 mg⁄day, which was not signiﬁcantly higher
than the average dose received in the double-blind
study, in which the average dose of oxycodone PR
was 34.0 mg⁄day and the average dose of oxycodone
PR⁄naloxone PR was 32.8 mg⁄day.
Efﬁcacy evaluation
The BFI score decreased throughout the extension
phase. After 12 months of treatment with oxycodone
PR⁄naloxone PR, in the LOCF analysis (n = 258),
the mean BFI score (±SD) fell from 35.6 ± 27.74
at baseline (end of the double-blind study) to
20.6 ± 24.01 by 12 months, which represents an
average 15-point reduction in BFI score (Figure 4).
These results were supported by the non-LOCF anal-
ysis (n = 250), in which the mean BFI score (±SD)
fell from 35.6 ± 27.74 at baseline to 20.4 ± 23.68 at
12 months.
Figure 4 Mean BFI by visit: bowel function study for the LOCF full extension population (n = 258) and score according
to double-blind phase treatment. BFI, Bowel Function Index; LOCF, last observation carried forward; PR, prolonged-
release
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results to categorise patients according to the treat-
ment they received during the double-blind study.
While all patients experienced improvements in BFI
score throughout the extension phase, the greatest
reduction in BFI was observed in those who switched
from oxycodone PR to oxycodone PR⁄naloxone PR
at the beginning of the extension phase. In these
patients, the mean BFI score (±SD; based on the
LOCF analysis) fell from 42.7 ± 28.61 at the start of
the extension phase to 26.1 ± 23.31 after 1 week of
treatment (Visit 10), compared with only a slight
reduction from 28.7 ± 25.15 to 26.2 ± 25.09 respec-
tively, for those who had received oxycodone
PR⁄naloxone PR in the double-blind phase. From
Week 1 onwards, the BFI fell at similar rates in the
two groups (Figure 4). At the end of the extension
phase, the mean BFI scores (±SD) decreased to
22.8 ± 25.59 and 18.6 ± 22.30 for patients who had
previously received oxycodone PR only in the dou-
ble-blind phase and those who had received oxyco-
done PR⁄naloxone PR respectively. The results were
similar for the non-LOCF analysis.
After switching to the extension phase, the mean
pain score (±SD) for the item ‘average pain over the
last 24 h’ was 3.3 ± 1.77, which was similar to the
combined mean pain score for the two treatment
arms at the end of the double-blind phase
(3.5 ± 1.87). The mean average pain scores (±SD)
were similar at all visits in the extension phase, being
3.1 ± 1.94 at 12 months. During the ﬁrst 7 days of
treatment, 75.3% of patient days were free from use
of analgesic rescue medication, and the mean (±SD)
daily rescue dose was low (2.51 ± 4.60 mg). The
mean (±SD) daily supplemental analgesic use was
also low (0.4 ± 0.64) during Days 1–7 of the exten-
sion phase. For the remainder of the study, require-
ment for other opioid analgesic medication (at the
investigator’s discretion) was reported by 83 patients
(32.2%). During the ﬁrst 7 days of the study, 24
patients (9.3%) received laxatives on a regular basis
and after the ﬁrst week, only 22 patients (8.5%)
reported regular laxative intake.
Safety evaluation
A total of 211 patients (81.8%) experienced an AE
during the extension phase (Table 5). Fewer than
half of the patients (125; 48.4%) experienced AEs
considered as having a causal relationship to study
medication, which were classiﬁed as serious for only
eight patients (3.1%). The most common AEs were
infections and infestations (104 patients, 40.3%), and
musculoskeletal and connective tissue disorders (104
patients, 40.3%). AEs led to study discontinuation in
3.5% of patients.
Gastrointestinal AEs occurred in 94 patients
(36.4%), with 40 (15.5%) experiencing constipation
and 18 (7.0%) experiencing diarrhoea. There was
one serious GI AE, although this case of abdominal
pain was considered as unlikely to be related to treat-
ment with oxycodone PR⁄naloxone PR. For patients
who experienced constipation or diarrhoea, only 29
(11.2%) and 7 (2.7%), respectively, were classed as
possibly, probably or deﬁnitely being related to treat-
ment. Only three patients (1.2%) experienced an epi-
sode of severe diarrhoea. Treatment for constipation
was given to 28 (10.9%) subjects but in no case did
constipation result in treatment discontinuation,
dose interruption or dose reduction.
One patient died during the study, but this was
because of necrotising faciitis and was not related to
treatment. A further 26 patients (10.1%) experienced
35 SAEs. Overall, 11 events in eight patients were
considered by the investigators to have a possible
relationship to the study medication and included
cardiovascular disorder, ECG and angina pectoris in
one patient, haematuria and bladder disorder in one
patient, and atrial ﬁbrillation, amnesia, non-cardiac
chest pain, myocardial infarction, abdominal pain
and cerebrovascular accident (one patient each).
Only one SAE (amnesia) was considered possibly
related to the study drug, for which treatment was
Table 5 Incidence of adverse events reported by system
organ class (‡ 10%) and preferred term (‡ 6%): bowel
function study extension population
Oxycodone
PR⁄Naloxone PR
(n = 258) %
Any adverse event 211 81.8
GI disorders 94 36.4
Constipation 40 15.5
Diarrhoea 18 7.0
General disorders and
administration site conditions
28 10.9
Infections and infestations 104 40.3
Musculoskeletal and connective
tissue disorders
104 40.3
Arthralgia 23 8.9
Back pain 35 13.6
Osteoarthritis 16 6.2
Nervous system disorders 58 22.5
Headache 18 7.0
Psychiatric disorders 31 12.0
Respiratory, thoracic and
mediastinal disorders
34 13.2
Skin and subcutaneous
tissue disorders
41 15.9
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the patient with the cerebrovascular accident. All
eight patients recovered from the AE, although
the patient with bladder disorder recovered with
sequelae.
Subjective Opiate Withdrawal Scale score remained
stable in the extension study, with the mean (SD)
score being 4.7 (5.68) after 1 week of treatment and
6.0 (6.36) at the end of the study (12 months). End-
of-study results for haematology, blood chemistry
and vital sign parameters were statistically equivalent
to their respective start-of-study values, as shown
post hoc by means of two-sided TOST analyses on
difference in [)1, +1] for basophils, eosinophils, total
bilirubin and direct bilirubin, or ratio in [0.8, 1.25].
Abnormal blood pressure or liver enzyme levels
were isolated. Changes in ECG were infrequent and
isolated.
Discussion
Efﬁcacy discussion
In the study focusing on analgesic efﬁcacy, the mean
score for the item ‘average pain over the last 24 h
scores and BPI-SF pain subscores were low and sta-
ble over 6 and 12 months, indicating that oxycodone
PR⁄naloxone PR provides effective long-term analge-
sic efﬁcacy. These results were supported by the
BPI-SF sleep quality item and interference subscores,
which correlated with the low pain scores, indicating
the positive effect of oxycodone PR⁄naloxone PR on
sleep and activities – an effect that was maintained
throughout the extension phase.
Following titration to an effective analgesic dose
during the ﬁrst 2 weeks of the extension study, the
majority of patients remained on an oxycodone
PR⁄naloxone PR dose comparable with that which
they received in the double-blind study. There was
no indication that the treatment that patients had
received in the double-blind study inﬂuenced the
dose increase after the ﬁrst 2 weeks. Some patients
did require an increase in dose; however, it is impor-
tant to note that this increase in mean daily dose of
oxycodone may reﬂect the natural progression of the
underlying pain-causing condition, which is sup-
ported by the slight increase in dose observed during
the 12-month extension phase. In addition, rescue
medication intake was low, which could also repre-
sent an additional factor affecting the increase in
study medication dose. A similar analgesic effect to
that observed in the total study population was seen
in the subpopulation of patients who received doses
>4 0⁄20 mg oxycodone PR⁄naloxone PR per day on
> 7 days consecutively – mean pain scores were sta-
ble and comparable at all study visits throughout the
extension phase. This also suggests that the long-
term analgesic efﬁcacy of oxycodone PR⁄naloxone
PR was maintained at higher doses.
In this study focusing on bowel function as the
main efﬁcacy measure, the mean BFI scores contin-
ued to improve over 52 weeks of treatment with
oxycodone PR⁄naloxone PR. Interestingly, patients
who had previously received oxycodone PR in the
double-blind phase experienced a rapid reduction in
BFI score during the ﬁrst week of treatment with the
ﬁxed combination of oxycodone PR⁄naloxone PR.
Following this, BFI scores decreased at a similar
rate to those in patients who had received oxyco-
done PR⁄naloxone PR in the double-blind study.
The improvement in OIC was achieved without
negatively affecting the analgesic efﬁcacy of the
oxycodone PR component, as mean pain scores
remained low and stable, and use of rescue medica-
tion was low throughout the study. This supports
the results from the extension study focusing on
analgesic efﬁcacy.
The results of these two extension studies show
that the efﬁcacy of the ﬁxed combination of oxyco-
done PR⁄naloxone PR observed in the previous 12-
week studies (22,23), in terms of both analgesia and
improvements in bowel function, can be achieved
and maintained during long-term therapy.
Safety discussion
In the analgesia study, the incidence of AEs in the
extension phase (68%) was comparable with that in
the double-blind study (oxycodone PR⁄naloxone PR
55.8%, oxycodone PR 53.0%, placebo 52.5%) when
the longer observation period was taken into account
(22). The most frequently-reported AEs were either
common side effects associated with opioid therapy
[constipation (9.2%) and nausea (7.7%)] or poten-
tially related to the underlying medical condition
[back pain (6.3%) and depression (6.3%)]. Although
88 SAEs occurred in this study, only 27 events in 12
patients were considered to have a causal relationship
with the study medication and only six events in
three patients were considered possibly related, but
no action was deemed necessary in terms of study
medication changes. Indeed, all three patients recov-
ered.
The incidence of GI AEs and nervous system dis-
orders was the highest in the ﬁrst 3 months of the
analgesia study. In this sensitive phase, all subjects
restarted opioid treatment with 20 mg oxyco-
done⁄naloxone, were uptitrated to their effective
analgesic dose and started new analgesic co-medica-
tion (oxycodone IR as rescue medication). Through-
out the next 9 months, the incidence of constipation
consistently decreased, dropping from six subjects at
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12 months. The incidence of constipation increased
again to 12 subjects within 7 days after the end of
oxycodone⁄naloxone treatment and the switch to a
marketed product. In 11 subjects, constipation was
assessed by the investigator as not related to study
medication (2.9%). Therefore, the incidence of con-
stipation related to study medication is reduced to
6.3%.
While 81.8% of patients experienced AEs in the
bowel function study, only 48.4% of these events had
a positive causal relationship to study medication;
only 26 patients experienced SAEs, the majority of
whom (n = 18) experienced SAEs that were not
related to study medication. Of the eight SAEs con-
sidered to have a possible relationship with the study
medication, only one was considered possibly related
to the study medication (amnesia), and for which
the treatment was discontinued and the patient
recovered. Importantly, the incidence of diarrhoea
was low, and SOWS sum scores were not exacerbated
with oxycodone PR⁄naloxone PR.
Based on the AEs, clinical laboratory reports, and
vital sign and ECG data, the long-term use of oxyco-
done PR⁄naloxone PR has a favourable tolerability
proﬁle. Furthermore, there was no indication of an
increased risk of AEs in patients taking doses
>4 0⁄20 mg⁄day oxycodone PR⁄naloxone PR for
> 7 days consecutively, compared with the total
extension phase population.
Discussion of study design, including choice of
treatment groups and appropriateness of
measurements
The study design allowed patients to be up-titrated
to 80⁄40 mg oxycodone PR⁄naloxone PR per day
and to take rescue medication. This ensured that
patients received adequate pain relief similar to the
usual practice of prescribing a dose of IR oxycodone,
as needed, for pain. The efﬁcacy measurements were
those commonly used to evaluate pain in patients
with chronic non-cancer pain and were consistent
with other studies in this development programme.
Moreover, the BFI (30,32) and the BPI-SF (29) with
the interference subscore used as a QoL measure are
validated instruments.
Conclusion
Opioid-induced constipation is the most frequently
reported AE experienced by patients receiving long-
term opioid therapy, and can cause signiﬁcant pain
and discomfort. In many cases, this can be sufﬁ-
ciently severe to undermine the effectiveness of pain
management and, therefore, negatively impact on
patients’ QoL. The results from these studies pro-
vide evidence that the ﬁxed combination of oxyco-
done PR⁄naloxone PR is a safe and efﬁcacious
agent for the long-term treatment of chronic pain.
Mean scores for the item ‘average pain over the last
24 h’ and BPI-SF pain subscores remained low and
stable throughout the 52-week study and were com-
parable with those observed at the end of the dou-
ble-blind study (22), indicating good analgesic
efﬁcacy. In addition to delivering consistent analge-
sia throughout 52 weeks, oxycodone PR⁄naloxone
PR continued to improve symptoms of OIC. This
supports the long-term use of oxycodone PR⁄nalox-
one PR in the treatment of chronic pain. The AEs
associated with oxycodone PR⁄naloxone PR are
consistent with those generally observed with opioid
therapy, and the combination of oxycodone PR
with naloxone PR raises no additional safety
concerns.
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